Once-Daily NUPLAZID® (pimavanserin) 34 mg Capsule

(Not actual size)*

*Actual size is 14.4 mm x 5.3 mm.

NUPLAZID RESPONDER ANALYSIS:

Real improvement for the majority of your PD psychosis patients

Once-Daily NUPLAZID® (pimavanserin) 34 mg Capsule

(Not actual size)*

*Actual size is 14.4 mm x 5.3 mm.

About 65% of NUPLAZID-treated patients experienced a clinically meaningful response vs 42% for placebo1*

Proportion of patients (responders) with SAPS-PD score improvement at end of Week 6 (N=185)1

Proportion of patients (responders) with SAPS-PD score improvement at end of Week 6
            (N=185)
 

~14% of NUPLAZID-treated patients experienced complete resolution of symptoms (SAPS-PD score reduced to 0 from baseline) vs 1% for placebo.1

26% of NUPLAZID-treated patients experienced a worsening of, or no change in their SAPS-PD scores vs 44% for placebo.1

Note: Complete response=SAPS-PD scores reduced to 0 from baseline value. Patients with missing values were counted as nonresponders.1

Based on regression analysis, a clinically meaningful 1-unit change in the CGI-I scale was associated with a 2.33-point change in SAPS-PD.2

 
Important Safety Information for NUPLAZID (pimavanserin)

Drug Interactions:

  • Coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole) increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily.
  • Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID.

 
For healthcare professionals